secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2024-10-09T23:59:59+00:00
Accession:  0000899923-24-000048
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics expects Q3 2024 revenue of $210-212M, reaffirms FY2024 guidance
-------------------------------------------------------------------------------

- Preliminary Q3 2024 revenue expected between $210M and $212M.
- Full-year 2024 revenue guidance reaffirmed at $835M-$845M.
- Divestiture of EndoPredict business in Europe closed on August 1, 2024.
- Results are preliminary and unaudited; subject to finalization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000048/0000899923-24-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000048/mygn-20241009.htm
  HTML page:      https://secwatch.observer/filing/0000899923-24-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer